Why Is Silence Therapeutics Stock Skyrocketing Monday?
Silence Therapeutics (SLN) leaps 126% on a $1.3B cash acquisition by Merck KGaA at $20 per ADS. Deal expected to close Q1 2027.
A big drug company called Merck KGaA is buying Silence Therapeutics for $1.3 billion. When a strong company buys a smaller one, it often means the smaller company had something valuable that caught their attention.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.